What is Axio Biosolutions Private?
Founded in 2008 and headquartered in Cambridge, Massachusetts, Axio Biosolutions is an ISO 13485-certified medical device enterprise dedicated to the advancement of wound care. The company is best known for its flagship product, Axiostat, a 100% chitosan-based haemostatic dressing engineered to control severe haemorrhage within minutes through active adhesion to trauma wounds. This innovative biopolymer technology has earned international recognition and is currently utilized by defense forces worldwide to address critical frontline medical needs. By bridging the gap between advanced material science and practical clinical application, Axio has established a defensible market position in the high-growth haemostasis segment.
How much funding has Axio Biosolutions Private raised?
Axio Biosolutions Private has raised a total of $18.6M across 2 funding rounds:
Series B
$12.6M
Other Financing Round
$6M
Series B (2020): $12.6M with participation from Chiratae Ventures, Omidyar Network India, University of California, and Accel
Other Financing Round (2021): $6M led by Accel, Omidyar Network India, TrueScale Capital, and UC Ratan Tata Fund
Key Investors in Axio Biosolutions Private
Chiratae Ventures
An established Indian technology venture capital fund advisor managing significant assets with a strong track record of supporting early-stage and portfolio companies through specialized programs.
Accel
A global venture capital firm that partners with exceptional teams from the inception of their ideas through all phases of private company growth.
Omidyar Network India
An investment firm focused on empowering entrepreneurs who tackle chronic social and economic problems in India through equity investments and philanthropic capital.
What's next for Axio Biosolutions Private?
Looking ahead, Axio Biosolutions is poised to leverage its recent capital injection to scale its operational footprint and deepen its research pipeline. The strategic focus will likely center on expanding the clinical utility of its chitosan-based platform, potentially entering new therapeutic areas within the wound care continuum. As the company matures, the integration of these funds will be pivotal in navigating regulatory landscapes and scaling production to meet the rising demand from global healthcare systems and emergency response units. The continued support from institutional investors suggests a long-term commitment to scaling Axio's impact as a leader in trauma-focused medical innovation.
See full Axio Biosolutions Private company page
